Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the recipient of a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 1,875 shares, a decline of 96.4% from the January 29th total of 52,373 shares. Based on an average daily trading volume, of 23,155 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company’s stock are short sold. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 23,155 shares, the short-interest ratio is currently 0.1 days.

Scinai Immunotherapeutics Stock Performance

Shares of Scinai Immunotherapeutics stock opened at $0.87 on Friday. Scinai Immunotherapeutics has a 1 year low of $0.61 and a 1 year high of $6.18. The firm’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $1.15. The firm has a market cap of $3.02 million, a PE ratio of -0.09 and a beta of 1.88.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC grew its position in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the quarter. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 58.41% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.